<DOC>
	<DOC>NCT00824460</DOC>
	<brief_summary>The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.</brief_summary>
	<brief_title>Study of Phosphate Levels in Patients With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Main â‰¥ 18 years of age, Receiving stable maintenance hemodialysis 3 times a week On restricted phosphate diet at screening and throughout study Receiving stable dose of phosphate binder for at least 1 month Serum phosphate levels &gt;1.78 mmol/L Main Uncontrolled hyperphosphatemia Hypercalcemia at screening or during washout Serum calcium &lt; 1.9 mmol/L (&lt;7.6 mg/dL) Severe hyperparathyroidism (iPTH levels &gt;600 ng/L) Pregnancy or lactation Iron deficiency anemia History of hemochromatosis or ferritin &gt;800 mg/L, Hepatitis B, hepatitis C or other significant concurrent liver disorders Known positivity to HIV Use of oral iron preparations 1 month before screening, Serious medical condition or uncontrolled systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hemodialysis</keyword>
</DOC>